Observational study / 2013
In postmenopausal non-NSAID users, higher urinary PGE-M was linked to increased breast cancer risk, with lifestyle factors associated with PGE-M levels.
Researchers evaluated the link between urinary prostaglandin E2 metabolite (PGE-M) and breast cancer risk using a case-cohort design with 307 incident cases and 300 subcohort members from the Sister Study. Smoking, a high-saturated fat diet, and obesity were associated with increased urinary PGE-M, whereas NSAID use decreased it. Although no overall association was found with breast cancer risk or among regular NSAID users, higher urinary PGE-M was positively associated with risk among women not regularly using NSAIDs (HRs of 2.1 [95% CI: 1.0-4.3], 2.0 [95% CI: 1.0-3.9], and 2.2 [95% CI: 1.1-4.3] for quartiles 2, 3, and 4 vs. quartile 1).
Shows an association, not proof of cause and effect.
- Study type
- Prospective case-cohort study
- Who was studied
- 307 incident breast cancer cases and 300 subcohort members from the Sister Study cohort (postmenopausal women)
- What was measured
- Association between urinary prostaglandin E2 metabolite (PGE-M) and postmenopausal breast cancer risk
THE PAPER
Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women.
Kim S, Taylor JA, Milne GL, Sandler DP. Cancer Prev Res (Phila), 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.